Vaccine for hepatitis B may allow patients to stop antiviral therapy
Most people with chronic hepatitis B enrolled in a Phase 2b clinical trial were eligible to discontinue their use of standard antiviral medication six…
Hepatitis
FDA gives green light to trial of HBV treatment GIGA-2339
The U.S. Food and Drug Administration (FDA) has given Gigagen the go-ahead to start clinical testing of GIGA-2339, its experimental treatment for hepatitis B…
CDA Foundation grants aim to help US hepatitis patients find doctors
In its efforts to connect diagnosed but untreated hepatitis B or C patients with physicians, the Center for Disease Analysis (CDA) Foundation has…
World Hepatitis Day calls for efforts to eliminate hepatitis by 2030
World Hepatitis Day, marked annually on July 28, seeks to raise awareness and help efforts to end viral hepatitis, a condition marked by liver…
WHO prequalifies 1st home test for hepatitis C
The World Health Organization (WHO) has prequalified the first self-test kit to detect the hepatitis C virus (HCV) in a home setting, marking…
FDA OKs clinical testing in US of hepatitis D combination treatment
The U.S. Food and Drug Administration (FDA) has approved Vir Biotechnology’s request to conduct clinical testing in the U.S. of a combination of two investigational…
HCV, HIV opt-out testing program to now be evaluated nationwide
A team of researchers, backed by a grant totaling more than $3 million, will study the feasibility of a nationwide opt-out testing program to detect…
Imdusiran plus immunotherapy may help in chronic hepatitis B
In ongoing proof-of-concept Phase 2a trials, Arbutus BioPharma’s imdusiran is showing an ability to possibly eliminate chronic hepatitis B infections when used in…
BJT-778 antibody therapy shows early promise in Hep D trial
Bluejay Therapeutics’ investigational antibody therapy BJT-778 appears to safely and effectively lower levels of the hepatitis D virus (HDV) and markers of liver inflammation…
Tobevibart, elebsiran can suppress hepatitis D virus: Phase 2 data
Vir Biotechnology’s investigational therapy tobevibart, used alone or in combination with another company candidate called elebsiran, can reduce hepatitis D virus (HDV) levels and…
